BMS 453 is a synthetic retnoid shown to be a RAR (retinoic acid receptor) antagonist. Studies note that this compound results in a block in the cell cycle at G1, causing an increase in ratio of cells in G0/G1. Further experiments suggest that BMS 453 induces Rb hypophosphorylation and lowers CDK2 kinase activity. BMS 453 also displays the capability to cause a conversion of latent transforming growth factor β (TGFβ) to active TGFβ. BMS 453 is an inhibitor of RAR α and RAR γ in vitro and an activator of RAR β in vivo.
1. Chen, J.Y., et al. 1995. EMBO J. 14: 1187-1197. PMID: 7720709 2. Yang, L., et al. 2001. Oncogene. 20: 8025-8035. PMID: 11753686 3. Yang, L., et al. 2001. Oncogene. 20: 8025-8035. PMID: 11753686
Soluble in DMSO (100 mM).
Store at -20° C
560.9° C at 760 mmHg (Predicted)
1.2 g/cm3 (Predicted)
n20D 1.66 (Predicted)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of
YangYang, L. et al. (PubMed 11753686) found that the retinoic acid receptor antagonist, BMS 453, inhibits normal breast cell growth by inducing active TGFbeta and causing cell cycle arrest. -SCBT Publication Review
To place an order using RMB or to ship to mainland China, please visit www.scbio.cn